AU2020337892B2 - Methods of treatment using BCN057 and BCN512 - Google Patents

Methods of treatment using BCN057 and BCN512

Info

Publication number
AU2020337892B2
AU2020337892B2 AU2020337892A AU2020337892A AU2020337892B2 AU 2020337892 B2 AU2020337892 B2 AU 2020337892B2 AU 2020337892 A AU2020337892 A AU 2020337892A AU 2020337892 A AU2020337892 A AU 2020337892A AU 2020337892 B2 AU2020337892 B2 AU 2020337892B2
Authority
AU
Australia
Prior art keywords
fibrosis
formula
cancer
day
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020337892A
Other languages
English (en)
Other versions
AU2020337892A1 (en
Inventor
Sudip CHAKRABORTTY
Andrew Norris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BCN BIOSCIENCES LLC
Original Assignee
BCN BIOSCIENCES LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BCN BIOSCIENCES LLC filed Critical BCN BIOSCIENCES LLC
Publication of AU2020337892A1 publication Critical patent/AU2020337892A1/en
Application granted granted Critical
Publication of AU2020337892B2 publication Critical patent/AU2020337892B2/en
Priority to AU2025267506A priority Critical patent/AU2025267506A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2020337892A 2019-08-24 2020-08-24 Methods of treatment using BCN057 and BCN512 Active AU2020337892B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025267506A AU2025267506A1 (en) 2019-08-24 2025-11-15 Methods of treatment using BCN057 and BCN512

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962891338P 2019-08-24 2019-08-24
US62/891,338 2019-08-24
PCT/US2020/047692 WO2021041347A1 (en) 2019-08-24 2020-08-24 Methods of treatment using bcn057 and bcn512

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025267506A Division AU2025267506A1 (en) 2019-08-24 2025-11-15 Methods of treatment using BCN057 and BCN512

Publications (2)

Publication Number Publication Date
AU2020337892A1 AU2020337892A1 (en) 2022-05-19
AU2020337892B2 true AU2020337892B2 (en) 2025-08-14

Family

ID=74647168

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020337892A Active AU2020337892B2 (en) 2019-08-24 2020-08-24 Methods of treatment using BCN057 and BCN512
AU2025267506A Pending AU2025267506A1 (en) 2019-08-24 2025-11-15 Methods of treatment using BCN057 and BCN512

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025267506A Pending AU2025267506A1 (en) 2019-08-24 2025-11-15 Methods of treatment using BCN057 and BCN512

Country Status (6)

Country Link
US (2) US11358964B2 (enExample)
EP (1) EP4017493A4 (enExample)
JP (3) JP2022545287A (enExample)
CN (1) CN114728001A (enExample)
AU (2) AU2020337892B2 (enExample)
WO (1) WO2021041347A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118541368A (zh) * 2021-09-03 2024-08-23 比西恩生物科学有限责任公司 使用bcn057、bcn077及类似物的治疗方法
US20240122916A1 (en) * 2022-10-08 2024-04-18 Radmit, Inc. Effect of YEL002 on Conditions and Diseases
US20240325375A1 (en) * 2023-04-01 2024-10-03 Radmit, Inc. Effect of YEL002 on Psychological and Psychiatric Factors in Health and Disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180104233A1 (en) * 2016-10-16 2018-04-19 BCN Biosciences L.L.C. Methods of treatment and pharmaceutical compositions using bcn057 or bcn512

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4159331A (en) * 1978-05-05 1979-06-26 The Upjohn Company Antihypertensive 4-aminoquinolines
US8227603B2 (en) * 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
WO2008016648A2 (en) * 2006-08-01 2008-02-07 Cytokinetics, Incorporated Certain chemical entities, compositions and methods
AU2018316185A1 (en) * 2017-08-08 2020-03-26 BCN Biosciences L.L.C. Methods of treating radiation induced gastrointestinal syndrome (RIGS) and related disease states using compound 512
AU2018346962A1 (en) * 2017-10-12 2020-05-28 BCN Biosciences L.L.C. Methods of treating radiation induced gastrointestinal syndrome

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180104233A1 (en) * 2016-10-16 2018-04-19 BCN Biosciences L.L.C. Methods of treatment and pharmaceutical compositions using bcn057 or bcn512

Also Published As

Publication number Publication date
AU2020337892A1 (en) 2022-05-19
US11358964B2 (en) 2022-06-14
CN114728001A (zh) 2022-07-08
AU2025267506A1 (en) 2025-12-11
JP2025032222A (ja) 2025-03-11
WO2021041347A1 (en) 2021-03-04
US20230035771A1 (en) 2023-02-02
EP4017493A4 (en) 2023-08-23
JP2026127687A (ja) 2026-08-06
US20210053968A1 (en) 2021-02-25
EP4017493A1 (en) 2022-06-29
US12435081B2 (en) 2025-10-07
JP2022545287A (ja) 2022-10-26

Similar Documents

Publication Publication Date Title
US12435081B2 (en) Methods of treatment using BCN057 and BCN512
CN112689629B (zh) 用于抑制Nav1.8的哒嗪化合物
ES2594378T3 (es) Derivados de la bencilidenoguanidina y uso terapéutico para el tratamiento de enfermedades por mal plegamiento proteico
JP6627835B2 (ja) Ｋｃｎｑ２〜５チャネル活性化剤
KR20160113287A (ko) 단백질 응집 저해제로서의 헤테로아릴 아미드
US20180162827A1 (en) Radiomitigating pharmaceutical formulations
KR20210102887A (ko) 말초 세로토닌과 관련된 질병 또는 장애를 치료하기 위한 트립토판 하이드록실라제 1 (tph1)의 결정질 스피로사이클릭 화합물 억제제
RU2013130878A (ru) Гидроксилированные производные аминотриазола в качестве агонистов рецептора alx
KR20150031481A (ko) 단백질 응집 저해제로서의 디- 및 트리-헤테로아릴 유도체
BRPI0712938A2 (pt) mÉtodo para modular excrescÊncia de neurito pelo uso de um antagonista de receptor de galanina-3
JP2025081626A (ja) ペンタミジンの類似体及びその使用
JP6197971B1 (ja) Ｋｃｎｑ２〜５チャネル関連疾患の予防および／または治療剤
US20180104233A1 (en) Methods of treatment and pharmaceutical compositions using bcn057 or bcn512
US20200368222A1 (en) Methods of treating radiation induced gastrointestinal syndrome (rigs) and related disease states using yel002/bcn057
US20240376098A1 (en) Methods of treatment using bcn057, bcn077 and analogs
EP3781149A1 (en) Acetylated prodrugs for delivery across the blood-brain barrier
WO2017156222A1 (en) Radiomitigating compounds, compositions and methods related thereto
KR20250046197A (ko) 티오벤즈이미다졸 유도체 또는 이의 약학적으로 허용가능한 염 및 이의 용도

Legal Events

Date Code Title Description
NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO ENTER THE NATIONAL PHASE HAS BEEN EXTENDED TO 24 APR 2022

FGA Letters patent sealed or granted (standard patent)